On September 1st, the efficacy and safety of vagus nerve stimulation for depresssion was published in the prestigious peer reviewed journal of Biological Psychiatry.
The data from the pivotal clinical trial of vagus nerve stimulation and depression was been on published September 1st, in the prestigious peer-reviewed journal of Biological Psychiatry. There were three articles published in Biological Psychiatry about VNS Therapy and depression. The articles confirm the association of VNS Therapy with significant antidepressant benefits that are sustained and/or growing over one year for patients with chronic or recurrent treatment-resistant depression. Secondly, the long-term safety of the procedure was confirmed.
"The response and remission and sustained long-term benefits realized by the patients treated with adjunctive VNS Therapy is remarkable, given that participants in the trials were some of the most treatment-resistant, depressed patients ever studied, with at least half having been hospitalized for the disease at least once," commented Dr. A. John Rush, MD, Professor and Vice Chairman for Research, Department of Psychiatry, Betty Jo Hay Chair in Mental Health, Rosewood Corporation Chair in Biomedical Science, University of Texas Southwestern Medical Center, Dallas, TX. "The VNS studies presented in these publications provide substantial evidence of a growing benefit of VNS Therapy over time when other treatments have not worked or have stopped working. This is particularly encouraging given the nature of treatment-resistant depression, a devastating and difficult to treat condition."
The publication of these articles is very important to you because third party payers (private insurance companies, Medicare, etc.) will help facilitate the approval of reimbursement of VNS Therapy for depression. Although reimbursement decisions will continue to be on a case-by-case basis, this is a critical next step which will be viewed very positively by insurance companies, Medicare as well as your psychiatrist.
You can learn more about this remarkable treatment at http://www.VagusNerveStimulator.com There is a free newsletter to keep you up-to-date on the latest developments on this first ever FDA approved long term treatment option for chronic or recurrent depression.
Charles Donovan was a study study subject in the FDA investigational trial of vagus nerve stimulation and chronic depression. He is the author of:
Out of the Black Hole: The Patient's Guide to Vagus Nerve Stimulation and Depression and founder of the VagusNerveStimulator.com Web site.
Out of the Black Hole: The Patient's Guide to Vagus Nerve Stimulation and Depression is available on Amazon.com, Barnes & Noble.com and at http://www.vagusnervestimulator.com/book/
Vagus Nerve Stimulation and Depression Conference
I attended the Vagus Nerve Stimulation and Depression Conference at the headuarters of the manufacturer of the vagus nerve stimulator in Houston. The meeting was attended by the leading psychiatric thought leaders in the United States.The scientists and researchers at the conference made the some comments that are important to you:20% of patients ...
Major Symposium About Vagus Nerve Stimulation & Depression at the American Psychiatric Association
A major symposium about vagus nerve stimulation as a treatment for chronic or recurrent depression will be presented at the American Psychiatric Association's Annual Meeting in May. This is the largest gathering of psychiatrists in the world and over 25,000 psychiatrists will be in attendance.On February 3, 2005, the FDA deemed vagus nerve stimulat...
Change Your Life Forever with New Medical Breakthrough Treatment for Depression
With the next few weeks, the FDA is expected to issue its final approval of vagus nerve stimulation as a treatment for chronic or recurrent depression. The approval of vagus nerve stimulation will be the first ever FDA approved long-term treatment option for the four million desperate Americans( and their families) who have not had an adequate resp...
Depression is the Number One Cause of Disability in the United States
According to the World Health Organization, 4 of the 10 leading causes of disability in the United States and other developed countries are mental disorders, including major depression, bipolar disorder, and schizophrenia. Approximately 23% of American adults each year have a diagnosable mental disorder and as many as 5.4% of American adults have a...
Vagus Nerve Stimulation as a Treatment for Depression to be Launched in May
Final FDA approval of vagus nerve stimulation as a therapy for chronic or recurrent treatment-resistant depression to be issued in May. Psychiatrists will then officially be able to prescribe this remarkable, life changing therapy for patients.On April 7th, 2005, the manufacturer of the vagus nerve stimulator( Cyberonics, Inc.) announced that it ha...
FDA Deems Vagus Nerve Therapy Approvable as a Treatment for Depression
On February 3, 2005 the U.S. Food and Drug Administration (FDA) notified the manufacturer of the vagus nerve stimulator (Cyberonics, Inc.) that it had deemed its VNS Therapy System approvable as a long-term adjunctive treatment for patients over the age of 18 with chronic or recurrent treatment-resistant depression in a major depressive episode tha...
Men, Women and Depression: Uniting Mind and Body in Our Healthcare Sytem
Men and depression, women and depression, it doesn't matter. Depression crosses all genders, ethnic groups and economic classes. The Centers for Disease Control studied the importance of integrating the mind with the body in our healthcare system. It is a fabulous study. I want to share the key points as they affect every family, family member or l...
